Do you want to read an article? Please log in or register.
Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer
Genitourinary Cancer
Related content
Breast Cancer
Recent Developments in Metastatic Breast Cancer
healthbook TIMES Oncology Hematology
Genitourinary Cancer
Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA
J Clin Oncol.
Oudard S, Fizazi K, Sengeløv L, Daugaard G, Saad F, Hansen S, Hjälm-Eriksson M, Jassem J, Thiery-Vuillemin A, Caffo O, Castellano D, Mainwaring PN, Bernard J, Shen L, Chadjaa M, Sartor O
doi: 10.1200/JCO.2016.72.1068.
Genitourinary Cancer
Impact of Prior Use of an Androgen Receptor-Axis-Targeted (ARAT) Agent With or Without Subsequent Taxane Therapy on the Efficacy of Another ARAT Agent in Patients With Metastatic Castration-Resistant Prostate Cancer
Clin Genitourin Cancer.
Miyake H, Hara T, Ozono S,
Fujisawa M
doi: 10.1016/j.clgc.2016.07.005.
Genitourinary Cancer
HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies
Ann Oncol.
Khalaf DJ, Aragón IM, Annala M, Lozano R, Taavitsainen S, Lorente D, Finch DL, Romero-Laorden N, Vergidis J, Cendón Y, Oja C, Pacheco MI, Zulfiqar M, PROREPAIR-B investigators., Gleave ME, Wyatt AW, Olmos D, Chi KN, Castro E
doi: 10.1016/j.annonc.2020.06.006.
Genitourinary Cancer
Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer
Eur J Cancer.
van der Doelen MJ, Isaacsson Velho P, Slootbeek PHJ, Pamidimarri Naga S, Bormann M, van Helvert S, Kroeze LI, van Oort IM, Gerritsen WR, Antonarakis ES, Mehra N
doi: 10.1016/j.ejca.2020.05.001.
Genitourinary Cancer
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial
Eur Urol.
Armstrong AJ, Lin P, Tombal B, Saad F, Higano CS, Joshua AM, Parli T, Rosbrook B, van Os S, Beer TM
doi: 10.1016/j.eururo.2020.04.061.
COMMENTED
Genitourinary Cancer
Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
Prostate.
Shore ND, Drake CG, Lin DW, Ryan CJ, Stratton KL, Dunshee C, Karsh LI, Kaul S, Kernen K, Pieczonka C, Sieber P, Stewart C, Williams M, Concepcion RS
doi: 10.1002/pros.24053.
Genitourinary Cancer
Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer
Eur J Cancer.
Caffo O, Gasparro D, Di Lorenzo G, Volta AD, Guglielmini P, Zucali P, Bortolus R, Cavo A, Ceresoli G, Chiari R, Fornarini G, Fratino L, Iaculli A, Maruzzo M, Masini C, Morelli F, Mucciarini C, Procopio G, Sabbatini R, Verri E, Kinspergher S, Maines F, Messina C, Veccia A, Donini M
doi: 10.1016/j.ejca.2020.09.018.
Genitourinary Cancer
Real-World Use of Bone Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer
J Natl Cancer Inst
Mitchell AP, Mishra A, Panageas KS, Lipitz-Snyderman A, Bach PB, Morris MJ
doi: 10.1093/jnci/djab196